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ABSTRACT 
The regulatory factors governing adult mesenchymal stem cells (MSCs) physiology and 
their tumorigenic potential are still largely unknown, which substantially delays the 
identification of effective therapeutic approaches for the treatment of aggressive and lethal 
form of MSC-derived mesenchymal tumors, such as undifferentiated sarcomas. Here we 
have developed a novel platform to screen and quickly identify genes and pathways 
responsible for adult MSCs transformation, modeled undifferentiated sarcoma in vivo, and, 
ultimately, tested the efficacy of targeting the identified oncopathways. Importantly, by 
taking advantage of this new platform, we demonstrate the key role of an aberrant LRF-
DLK1-SOX9 pathway in the pathogenesis of undifferentiated sarcoma with important 
therapeutic implications.  
 
SIGNIFICANCE 
The paucity of therapeutic options for the treatment of sarcoma calls for a rapid and 
effective preclinical assessment of new therapeutic modalities. We have here developed a 
new platform to deconstruct the molecular genetics underlying the pathogenesis of sarcoma 
and to evaluate in vivo the efficacy of novel targeted therapies. 
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INTRODUCTION 
Tumorigenesis and stem cell differentiation are frequently tied together, in the way that, 
genetic and functional loss of genes responsible for cell commitment and differentiation are 
selected during the tumorigenic process, since undifferentiated cells are often endowed with 
longer life spans, higher survival and proliferative potential, and are often resistant to 
treatment (1).  
Adult mesenchymal stem cells (MSCs) are known for their ability to self-renew as well 
as differentiate into cells of varying mesenchymal lineages, such as chondrocytes, 
osteoblasts and adipocytes (2, 3). Importantly, mounting evidence now implicates adult 
MSCs as the cell of origin of human undifferentiated sarcomas, one of the most aggressive 
and lethal soft tissue tumors (4-8). Undifferentiated sarcomas are generally treated by 
surgical resection (whenever possible), radiotherapy, and chemotherapy; all options, 
however, that minimally change the very poor overall survival in patients. Limited genetic 
and molecular analyses, along with the absence of faithful in vivo models enabling pre-
clinical testing of targeting specific tumorigenic pathways, are together the main factors 
impeding the development of new and more effective therapeutic options. While specific 
forms of sarcoma (i.e. osteosarcoma) have been successfully modeled in genetically 
engineered mice (9-12), current protocols to model undifferentiated sarcomas are generally 
based on transplantation of human tumor cell lines in immune compromised mice (13), in 
vitro expanded, and spontaneously transformed heterogeneous mouse primary 
mesenchymal cells (4, 14, 15), or in vitro-genetically modified human bone marrow MSCs 
(16, 17), whose purity and stemness features have recently been debated (3, 18). Although 
these studies have proved helpful in uncovering aspects of sarcomagenesis, such protocols 
fail to mirror the real onset and progression of undifferentiated sarcomas since they cannot 
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control key factors such as the type and number of the genetic alterations driving the 
tumorigenic process, or cell of origin (19). In turn, these approaches will hardly allow the 
discovery of key genetic drivers involved in the onset and progression of undifferentiated 
sarcomas, and, most importantly, of potential druggable targets with clinical relevance. To 
fill this void, we have developed a novel ex vivo/in vivo genetic platform that will allow the 
discovery of genetic drivers responsible for adult MSC transformation and the generation, 
in vivo, of undifferentiated sarcomas.  
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RESULTS 
Optimized culture conditions to prevent MSCs spontaneous transformation lead to 
the development of a new genetic platform to model sarcomagenesis 
In order to model undifferentiated sarcomas, we selectively isolated from the bone marrow 
of mice a cell population highly enriched for adult MSCs (20, 21) (BM-MSCs: CD45
-
CD31
-
Ter119
-
Sca1
+PDGFRα+, Fig. 1A), grew them in vitro, in conditions that maintain 
their stemness properties, and then studied the genetic drivers leading to their 
transformation. We have recently described that mimicking in vitro the hypoxic conditions 
characterizing the natural environment of MSCs within the bone, favors the expansion of 
adult BM-MSCs, while maintaining their stem features (21). This analysis led us to 
discover that, unexpectedly and in contrast with what has been previously reported for 
mesenchymal cells cultured in regular oxygen concentrations (20% oxygen) (4, 14, 15, 22), 
primary adult BM-MSCs cultured in hypoxic conditions (1% oxygen) did not undergo 
spontaneous in vitro transformation; on the contrary they showed progressive reduction in 
the proliferation rate during the culture (Fig. 1B). Moreover, once seeded into scaffolds and 
implanted subcutaneously in mice, MSCs remained vital even after months, showing 
abilities to recruit blood vessels within the scaffold, but not to form tumors, or to show 
marks of neoplastic transformation (Fig. 1C).  
Loss of p53 has been firmly implicated in the pathogenesis of undifferentiated 
sarcomas in human (23). We therefore assessed the impact of p53 inactivation in our model 
system. Differently to wild type MSCs, primary p53
KO
 adult MSCs maintained in vitro in 
hypoxic conditions were characterized by high proliferation rate even after numerous 
passages, as evidences of a status of immortalization (Fig. 1D). Surprisingly, however, 
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p53
KO
 MSCs did not show signs of neoplastic transformation in hypoxic growth conditions 
in vitro, such as the ability to form foci of transformation in the dedicated assay or sizable 
colonies in soft agar (Fig. 1D). In order to test their tumorigenic potential in vivo, we next 
seeded p53
KO
 MSCs into scaffolds (24) and transplanted them subcutaneously in syngeneic 
C57BL/6, or nude mice (1
rst
 recipients). Two months after the implantation, the scaffolds 
were collected, cells within them were expanded in hypoxic conditions, and were then used 
for a second round of implantation (2
nd
 recipients) (Fig. 1E). Similarly to wild type MSCs, 
p53
KO
 MSCs remained vital within scaffolds. They recruited blood vessels, and they did not 
show any signs of neoplastic transformation in both 1
rst 
and 2
nd
 recipients, which resulted in 
the inability to generate tumors in serially transplanted animals (Fig. 1F).  
Previous published data reported spontaneous transformation of murine MSCs cultured 
in regular oxygen conditions after several passages (14, 15). We therefore analyzed the 
spontaneous transformation of p53
KO
 MSC populations culturing them for 1 month or 4 
months in low (1%) or high (20%) oxygen tension, and then performed a “focus formation 
assay”. As shown in Figure 1G, cells cultured for 1 month at 1% of oxygen were not able to 
generate transformed foci; while, on the contrary, cells kept at 20% of oxygen formed 
several foci of transformation, which increased in number and size during the culture. 
Importantly, we also noticed that MSC cultures kept at 20% of oxygen showed a significant 
increase in the number of cells characterized by several (n>5) nuclear dots of γH2AX in 
comparison to the same cells kept at 1% of oxygen (Supplementary Fig. S1A), thus 
defining a condition of increased DNA damage linked to the 20% oxygen condition, 
primary cause of genomic instability in replicating cells (25). 
Overall, these data led us to hypothesize that loss of p53 functions in human MSCs may 
be necessary but not sufficient to trigger sarcomagenesis. In addition, in vitro hypoxic 
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growth conditions, by maintaining genomic stability of primary adult p53-null MSCs and 
by preventing their spontaneous neoplastic transformation, might represent the cornerstone 
for the development of a tightly controlled genetic platform aimed at identifying specific 
genetic alterations that, in combination with p53 loss, could dictate adult MSCs 
transformation and development of undifferentiated sarcomas. To test this hypothesis, we 
decided to challenge our platform with oncogenic stresses previously implicated in 
sarcomagenesis, and assess their capacity to transform p53-null MSCs. Specifically, in p53-
null MSCs maintained in hypoxic conditions we over-expressed c-myc (26), K-Ras
G12V 
(27) 
and IDH2
R172K 
(13), while we knocked-down Pten (28). The expression of c-myc and K-
Ras
G12V
, as well as the loss of Pten (but not the expression of IDH2
R172K
) were indeed able 
to trigger p53-null MSCs transformation in vitro, and represented proofs of principle for the 
validity of our approach (Fig. 1H and Supplementary Fig. S1B-G). 
 
Identification of novel genes involved in sarcomagenesis through the MSC-derived 
platform 
We next tested whether this new platform would be useful in identifying new genes 
implicated in sarcomagenesis. Since undifferentiated sarcomas have been suggested to 
originate through the combined deregulation in adult MSCs of genes involved in cellular 
proliferation/apoptosis (such as p53), and genes implicated in the regulation of stem cell 
differentiation (29, 30), we decided to couple two known regulators of stem cells 
maintenance and differentiation with the loss of p53. The regulators enrolled in the 
platform were PML (31) and LRF/Pokemon [encoded by the gene ZBTB7A (Zinc finger 
and BTB domain-containing protein 7A)], which is emerging as one of the master 
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regulators of differentiation for both hematopoietic and non-hematopoietic stem/progenitor 
cells, and has been attributed oncogenic or tumor suppressive functions depending on the 
specific cellular context (32). While Pml knockdown in p53-null MSCs did not trigger 
neoplastic transformation, adult p53-null MSCs knocked down for Lrf, showed features of 
neoplastic transformation in vitro (Fig. 1H and Supplementary Fig. S1F-G), suggesting a 
possible role for LRF as suppressor of sarcomagenesis. In order to fully determine this new 
role of Lrf/Pokemon in sarcomagenesis, we generated a cohort of p53
KO
Zbtb7a
F/F
 mice, and 
derived adult MSCs as previously described (Fig. 1A). Zbtb7a was knocked out in vitro by 
transducing p53
KO
Zbtb7a
F/F
 MSCs with lentiviral vectors containing CRE cDNA, or an 
empty vector as control (hereafter referred to as p53
KO
Zbtb7a
F/F
-CRE or p53
KO
Zbtb7a
F/F
-
CTR for brevity) (Supplementary Fig. S2A). Although p53
KO
Zbtb7a
F/F
-CRE and
 
p53
KO
Zbtb7a
F/F
-CTR cells showed similar anchorage-dependent growth rate 
(Supplementary Fig. S2B), the anchorage-independent colony-forming capacity of 
p53
KO
Zbtb7a
F/F
-CRE cells, as well as the capacity to form transformation foci in vitro, was 
significantly higher than that of p53
KO
Zbtb7a
F/F
-CTR cells (Fig. 2A and data not shown). 
Off-target effects of the CRE infection were ruled out upon transduction of p53
KO
Zbtb7a
+/+
 
cells with the same lentiviral vectors containing CRE cDNA, or an empty vector as control 
used in p53
KO
Zbtb7a
F/F 
cells, and then performing a focus formation assay (Supplementary 
Fig. S2C).  
 Finally, in order to test their tumorigenic potential in vivo we seeded p53
KO
Zbtb7a
F/F
-
CRE or
 
p53
KO
Zbtb7a
F/F
-CTR MSCs into the scaffolds and implanted them into mice 
following the same protocol described in figure 1E. Two months after implantation, we 
observed that p53
KO
Zbtb7a
F/F
-CTR cells were not able to generate tumor in mice (as 
expected, only non-transformed mesenchymal cells were recovered from the scaffolds), 
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while the p53
KO
Zbtb7a
F/F
-CRE cells underwent neoplastic transformation and generated 
tumors in all the transplanted mice (Fig. 2B). Cells were then recovered from the scaffolds, 
characterized for Lrf expression (Supplementary Fig. S2D), and further tested for their 
neoplastic potential in vitro, and then in vivo in a second round of transplantation. Once 
again, p53
KO
Zbtb7a
F/F
-CRE and
 
p53
KO
Zbtb7a
F/F
-CTR cells recovered from the scaffold 
showed similar rates of anchorage-dependent proliferation (Supplementary Fig. S2E), but 
only the p53
KO
Zbtb7a
F/F
-CRE cells displayed the capacity to form transformed foci (Fig. 
2C). Importantly, once re-transplanted in secondary recipients (2
nd
 recipients), 
p53
KO
Zbtb7a
F/F
-CRE cells originated tumors larger than 5 mm in less than two weeks (7/7 
mice; 2 nude mice and 5 C57Bl/6), while none of the 4 mice (2 nude mice and 2 C57Bl/6) 
re-transplanted with p53
KO
Zbtb7a
F/F
-CTR cells originated tumors (Fig. 2D-G). 
Histopathological analysis of scaffolds recovered from mice revealed that p53
KO
Zbtb7a
F/F
-
CRE cells originated undifferentiated sarcomas, which were able to egress the scaffolds and 
to invade tissues nearby. On the contrary, only non-transformed mesenchymal cells were 
present in the scaffolds implanted with p53
KO
Zbtb7a
F/F
-CTR cells (Fig. 2F-G).  
Since our platform identified Lrf as a tumor suppressor gene in triggering the 
transformation of MSCs, we investigated the expression of LRF through 
immunohistochemistry analyses on a comprehensive human tissue microarray (TMA) 
containing n=45 undifferentiated mesenchymal tumors (fibrosarcomas (F.) and n=20 
malignant fibrous hystocytomas, (M.F.H)), compared to n=4 normal fibrous tissues 
(N.F.T.) (Fig. 2H). All normal fibrous tissues (4/4) as well as human adult MSCs 
(Supplementary Fig. S2F) were characterized by LRF expression, while, in sharp contrast, 
malignant undifferentiated sarcomas turned out strongly negative, (41/45 cases of 
fibrosarcomas and 19/20 case of malignant fibrous hystocytomas).  
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Overall, these results demonstrate that our platform may turn out as an important tool to 
identify new oncogenes and tumor suppressors involved in the development of human 
sarcomas.  
 
LRF is essential for MSCs commitment and differentiation 
We next investigated the biological processes through which LRF loss could trigger 
sarcomagenesis. LRF/Pokemon has been described in the stemness 
maintenance/differentiation in different cell lineages (32), however, nothing is known about 
its role in adult MSCs. For this reason, we first investigated the possibility that Lrf could 
trigger sarcomagenesis by blocking the differentiation capacity of MSCs. Accordingly, we 
derived MSCs from Zbtb7a-floxed mice (Zbtb7a
F/F
) and investigated their 
commitment/differentiation ability towards osteoblasts, chondrocytes, and adipocytes upon 
Lrf knock out in vitro through transduction with CRE-lentiviral vector (from now referred 
as CRE-cells or CTR-cells). Despite the profound reduction of Lrf expression 
(Supplementary Fig. S3A), CRE-cells remained similar to CTR-cells in terms of 
morphology, size and number of the CFU-F colonies generated (Supplementary Fig. S3B), 
as well as to numbers of cells undergoing to senescence (Supplementary Fig. S3C) or to 
apoptosis (Supplementary Fig. S3D-E). However, as shown in Fig. 3A-E, CRE-cells 
displayed differentiation defects when compared to CTR-cells. CRE-cells generated only 
30% of the Oil-Red-O positive CFU-F colonies generated by CTR-cells in response to 
adipogenic induction (Fig. 3A), and accordingly, the expression of Ppar and Fabp4 during 
differentiation was significantly lower in CRE-cells compared to CTR-cells (Fig. 3B). 
Similarly, CRE-cells treated with osteogenic stimulating factors originated less Alp
+
-
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osteoblasts than CTR-cells (Fig. 3C) and, CRE-cells expressed lower levels of Alp and 
osteocalcin (Oc) mRNAs compared to controls (Fig. 3D). Finally, regarding 
chondrogenesis, CRE-cells originated chondrocyte micro-masses surrounded by less 
extracellular matrix (as shown by Toluidine blue staining) than CTR-cells. Interestingly, 
CRE-cells expressed significantly higher amounts of Col2 in comparison to CTR-cells, 
although the expression of markers of terminal differentiation such as ColIX and ColX was 
significantly reduced suggesting that chondrocyte progenitors are favored in their initial 
commitment, yet they fail to reach a mature terminal differentiation (Fig. 3E).  
Finally, to corroborate our findings in human MSCs (hMSCs), LRF was knocked down 
through specific shRNAs taking advantage of commercially available hMSCs cultured 
under the same conditions used for mouse MSCs. The ability of sh-LRF and sh-CTR 
hMSCs to originate mature adipocytes was evaluated as previously described for mouse 
MSCs. Both shLRF and shCTR transduced hMSCs behaved comparably in culture, without 
displaying features of apoptosis or senescence (Figure 3F). However, while shCTR-hMSCs 
showed initial signs of adipocytic differentiation starting from day 7 (Figure 3G) and were 
fully differentiated at day 15 (Figure 3H), shLRF-hMSCs remained completely 
undifferentiated at day 7 (Figure 3G), and generated only few mature cells at day 15. 
Accordingly, expression levels of FABP4 were reduced in shLRF-hMSCs compared to 
shCTR-hMSCs (Figure 3H). Analysis of human MSCs therefore confirms the results 
obtained in mouse MSCs, as well as the evolutionary conserved critical role for LRF in 
determining MSCs cell fate decisions. 
 
Lrf promotes MSCs commitment through the transcriptional repression of Dlk1  
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Based on these data showing that LRF/Pokemon governs the commitment capacity of 
MSCs, and having excluded a possible role of two well characterized pathways regulated 
by LRF/Pokemon such as ARF (33) and NOTCH1 (34) in this process (data not shown), we 
aimed to understand which pathways are regulated by Lrf in MSCs, in order to identify 
possible new players involved in the genesis of undifferentiated sarcoma and, in turn, 
potential targets for therapy. Considering that oncogenic and tumor suppressive pathways 
are often wired to regulate cell lineage commitment and differentiation in physiological 
conditions (35), we focused our attention on DLK1 (Delta-like-1)/SOX9 (SRY (sex 
determining region Y)-box 9) pathway, that is know to be critical in mesenchymal lineages 
determination (36-40). In particular, we focused on SOX9, as it has been shown to be 
involved in the differentiation process of MSCs (41), in addition to being recently described 
as functionally antagonized by Lrf in prostate tumorigenesis (42, 43). CTR-cells and CRE-
cells were first analyzed by RT-qPCR for the expression of Sox9 transcriptional target 
genes (44, 45); both genes were over-expressed in CRE-cells as compared to CTR-cells 
(Fig. 4A). Similarly, the knock-down of LRF in hMSCs resulted in the up-regulation of 
SOX9-activity (Figure 4B). Next, in order to address the critical question of whether Lrf 
mediates MSC commitment through Sox9, CRE-cells were knocked down for Sox9 
(Supplementary Fig. S4A), and induced to differentiate. CTR-shSCR-cells, CRE-shSCR-
cells and CRE-shSox9-cells originated a comparable number of colonies as detected by 
crystal violet, while down-regulation of Sox9 levels and activity did not rescue the capacity 
of CRE-cells to differentiate into mature adipocytes (Fig. 4C and Supplementary Fig. S4B-
C). Similarly, down-regulation of Sox9 in CRE-cells negligibly rescued the ability of MSCs 
to differentiate into mature osteoblasts (Fig. 4D). 
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Another critical regulator of MSCs commitment is DLK1 (46-50). We therefore 
decided to investigate the possibility that Lrf could regulate Dlk1 activity, and through it 
the commitment of MSCs. Intriguingly, CRE-cells showed a significant increase in Dlk1 
expression compared to CTR-cells (Fig. 4E). Similarly, knock-down of LRF resulted in the 
up-regulation of DLK1 in hMSCs (Figure 4F). To determine whether Lrf could directly 
regulate Dlk1 expression, we cloned the Dlk1 promoter sequence into a luciferase construct 
and performed in vitro transactivation assays. This analysis revealed that Lrf efficiently 
repressed the basal promoter activity in a dose-dependent manner (Fig. 4G), and, among the 
six putative Lrf consensus regions within the promoter of Dlk1, we discovered that only the 
two consensus sequences (indicated as 4 and 5 in Supplementary Fig. S4D), closest to the 
transcriptional starting site, were necessary for Lrf repression of Dlk1 transcription. 
Additionally, the ability of Lrf to bind Dlk1 promoter was confirmed performing 
electrophoretic mobility shift (EMSA) assays (Fig. 4H), and chromatin-
immunoprecipitation (ChIP) (Fig. 4I) in 3T3L1 mouse mesenchymal cell line. In order to 
functionally validate the Lrf/Dlk1 axis in MSC commitment, we knocked down Dlk1 in 
CRE-cells, and induced the generated cells to differentiate toward adipocytes and 
osteoblasts. As expected, CRE-shSCR-cells failed to differentiate compared to CTR-
shSCR-cells; but, critically, the concomitant inactivation of Dlk1 (CRE-shDlk1-cells) 
rescued their defects of adipogenesis (Fig. 4J-K and Supplementary Fig. S4E-F), and 
osteogenesis (Fig. 4L-M). 
 
Lrf acts as oncosuppressor of mesenchymal tumorigenesis by controlling the activity 
of Dlk1 and Sox9  
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Both DLK1 and SOX9 have been described as oncogenes in several tumor types (36-39). 
Since we have demonstrated that Lrf negatively controls both the expression of Dlk1 and 
the activity of Sox9 in primary non-transformed MSCs, and that, in a p53-null MSCs, Lrf 
acts as a tumor suppressor gene, we next used our platform in order to investigate the 
possibility that Dlk1 and Sox9 deregulation might be responsible for transformation of 
MSCs and sarcomagenesis after Lrf loss. p53
KO
Zbtb7a
F/F
-CRE cells or p53
KO
Zbtb7a
F/F
-
CTR cells collected from scaffolds (1
st
 recipient), were grown in hypoxia for 7 days and 
then transduced with shRNA in order to silence Dlk1 or Sox9. Four different cellular types 
were then obtained: p53
KO
Zbtb7a
F/F
-CTR-shSCR, p53
KO
Zbtb7a
F/F
-CRE-shSCR, 
p53
KO
Zbtb7a
F/F
-CRE-shDlk1 and p53
KO
Zbtb7a
F/F
-CRE-shSox9 (in the figures indicated 
only as CTR-shSCR, CRE-shSCR, CRE-shDlk1 and CRE-shSox9 for brevity) (Fig. 5A and 
Supplementary Fig. S5A-B). Cells were then used both in vitro and in vivo experiments to 
test their tumorigenic potential. In an anchorage-dependent proliferation assay, all the cell 
types showed similar division rates (Fig. 5A), but their capacity to form transformed foci in 
the culture was significantly different. While p53
KO
Zbtb7a
F/F
-CRE-shSCR cells were 
extremely prone to form foci of transformation, down regulation of Dlk1 (p53
KO
Zbtb7a
F/F
-
CRE-shDlk1) or Sox9 (p53
KO
Zbtb7a
F/F
-CRE-shSox9) in p53
KO
Zbtb7a
F/F
-CRE cells 
significantly limited their oncogenic potential in vitro (Fig. 5B and Supplementary Fig. 
S5C). In order to analyze in vivo the possible implications of Dlk1 and Sox9 hyperactivity 
in the tumorigenic process induced by the absence of Lrf, we transplanted scaffolds 
containing CTR-shSCR, CRE-shSCR, CRE-shDlk1 or CRE-shSox9 cells subcutaneously in 
the flank of recipient mice, and then evaluated their tumorigenic potential. One month after 
implantation, 4/4 mice implanted with scaffolds containing p53
KO
Zbtb7a
F/F
-CRE-shSCR 
cells, 4/5 mice implanted with scaffolds containing p53
KO
Zbtb7a
F/F
-CRE-shDlk1 cells and 
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3/5 mice implanted with scaffolds containing p53
KO
Zbtb7a
F/F
-CRE-shSox9 cells developed 
visible tumors, while no tumors were observed in mice implanted with scaffolds containing 
p53
KO
Zbtb7a
F/F
-CTR-shSCR cells (0/4) (Fig. 5C). Although 80% of mice implanted with 
p53
KO
Zbtb7a
F/F
-CRE-shDlk1 and 60% of mice implanted with p53
KO
Zbtb7a
F/F
-CRE-
shSox9 MSCs developed tumors, these lesions were significantly smaller than the 
p53
KO
Zbtb7a
F/F
-CRE-shSCR tumors (Fig. 5D), and only a few transformed multinucleated 
cells were present within the scaffolds containing p53
KO
Zbtb7a
F/F
-CRE-shDlk1 cells or 
p53
KO
Zbtb7a
F/F
-CRE-shSox9 cells (Fig. 5E), revealing that both these two oncogenes 
participate to undifferentiated sarcoma formation from MSCs .  
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DISCUSSION 
Adult MSCs have been proposed as the cell of origin of human undifferentiated sarcomas, 
one of the most aggressive and lethal soft tissue tumors (4-8). However, a comprehensive 
analysis of the molecular mechanisms dictating the onset and progression of 
undifferentiated sarcomas is still missing, consequently, limiting the generation of pre-
clinical models faithfully recapitulating the human disease, and more importantly, the 
development of new and effective therapeutic options for this lethal tumor. A major current 
hurdle in studying and modeling the pathogenesis of sarcoma is represented by the need to 
deliver the appropriate genetic perturbation(s) to a specific putative cell of origin (19). 
Here, we employed primary adult mouse bone marrow MSCs sorted according to the 
expression of specific markers, and tested for stemness potential. By modifying their 
culturing condition, we have developed a new experimental ex vivo/in vivo platform to 
deconstruct the molecular genetics underlying the pathogenesis of undifferentiated 
sarcomas. Comparable findings were obtained using commercially available unsorted 
human MSC. It must be noted however that recent reports question the use of unsorted 
human MSCs collected from bone marrow and solely selected on their ability to adhere to 
culture dish for their inherent heterogeneity (3). Our approach nevertheless rests on the 
discovery that culturing mouse and human MSCs in hypoxic conditions prevents their 
spontaneous propensity to transform. As we recently reported, MSCs reside in bone 
marrow areas characterized by low oxygen concentration. Compared to other stromal cells 
within the endosteal bone marrow, MSCs express higher levels of HIF-1α and HIF-2α 
transcripts, showing a distinctive hypoxic profile (21). Therefore, the enforced switch from 
an anaerobic to an aerobic environment due to culturing in a 20% oxygen condition could 
determine excessive levels of reactive oxygen species (ROS) and, in turn, increasing 
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amount of unrepaired DNA damage, prelude to genetic instability and neoplastic 
transformation. By preventing the spontaneous transformation of wild type as well as p53-
null MSCs, this new approach will turn out to be very useful to: i) quickly asses the 
relevance of specific genetic alterations within the tumorigenesis process of MSCs; ii) 
characterize oncogenic or oncosuppressive functions and molecular pathways controlled by 
the newly identified genetic alterations; iii) to evaluate, pre-clinically, both in vitro and in 
vivo (in mice implanted with scaffolds), the efficacy of novel targeted therapies towards the 
eradication of this lethal disease (Fig. 5F). The relevance of this new approach is based on 
its ability to control the cell of origin of the disease, its simplicity and velocity. 
Furthermore, it can easily be coupled with the use of shRNA/over-expressing 
vectors/libraries in vitro, or the new developing system Crispr/Cas9 for genome editing of 
both coding and non-coding genes to be tested individually or in combination. Importantly, 
we demonstrate the utility of this discovery platform. Specifically, we have defined a role 
for LRF as tumor suppressor gene in adult MSCs and identified LRF as a key factor in the 
control of the early steps of adult MSC commitment. Additionally, we have characterized 
two evolutionary conserved oncosuppressive mechanisms regulated by LRF in adult MSCs: 
its ability to transcriptionally repress DLK1 expression, and to inhibit SOX9 activity (Fig. 
5G). DLK1 is a trans-membrane protein that, once cleaved by enzyme TACE/ADAM17, 
releases the soluble factor FA-1 (fetal antigen-1) (51). Thus, the use of neutralizing 
antibodies against DLK1 (52), alone or in combination with inhibitors of SOX9 down-
stream factors may offer a window of opportunity for the development of novel therapeutic 
strategies for this lethal form of cancer.  
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METHODS 
Mice 
Transgenic mice Zbtb7a
fl/fl
 were generated as described (34); p53
KO
 mice were purchased 
from The Jackson Lab, and generated as described (53). All the experimental animals were 
kept in C57Bl/6J pure background. In some specific experiments immunodeficent mice 
were used (The Jackson Lab B6.Cg-Foxn1
nu
/J). Animal experiments were performed in 
accordance with the guidelines of the Institutional Animal Care and Use Committee. 
Cell Lines and human MSCs 
3T3-L1 cells were purchased from ATCC (ATCC-CL-173) and cultured following the 
vendor direction. Cell lines were tested for mycoplasma (MycoAlert, Lonza), but not 
further authenticated. Human MSC were purchased from Lonza (PT-2501). According to 
the vendor cells are positive for CD105, CD166, CD29, and CD44, and test negative for 
CD14, CD34 and CD45. Cells were cultured and induced to differentiate following the 
vendor directions, but not further authenticated. Cells were maintained in culture with 
mesenchymal stem cell basal medium (Lonza, PT-3238) supplemented with growth factors 
(Lonza, PT- 3001). During adipogenesis cells were cultured in adipogenic induction 
medium (Lonza, PT-3102B), followed by adipogenic maintenance medium (Lonza, PT-
3102A), according to the vendor instructions.  
Mesenchymal Stem Cells maintenance  
MSCs were derived from C57BL/6 wild type, Lrf
F/F
, and p53
ko
Lrf
F/F 
mice. Long bones 
were collected, crushed and digested with collagenase II (1mg/ml) for 1 hour shaking at 
37°C. Recovered cells were stained and FACS-sorted as: CD45
-
CD31
-
Ter119
-
Sca1
+
PDGFR+, and cultured at the density of 1000 cells in a T25 flask. MSCs were 
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cultured using complete MesenCult medium (STEMCELL Technologies) and maintained 
in humidified chamber with 5% CO2 and 1% O2, half medium was changed every 3 days. 
After 7 days in culture at 1% O2 cells formed visible CFU-F colonies, after this point cells 
were split once reached 80% of confluence.  
Mesenchymal Stem Cells differentiation 
MSCs were cultured using complete MesenCult medium (STEMCELL Technologies) and 
maintained in humidified chamber with 5% CO2 and 1% O2. For inducing the 
differentiation, the MesenCult medium was changed with specific medium for each 
differentiation (see below). During the differentiation process cells were maintained in 
regular oxygen concentration, 5% CO2 and 37°C. For adipocytes differentiation MSCs 
colonies were treated with StemXVivo™ Osteogenic/Adipogenic medium (R&D Systems, 
CCM007) plus adipogenic supplements (R&D Systems, CCM011). Medium was changed 
every other day for 7 days. Mature adipocytes were identified with Oil-Red-O (Sigma) 
following manufacturer procedure. Briefly, Oil-Red-O stock solution was prepared 
solubilizing Oil-red-O powder in isopropanol (0,35g/100ml isopropanol), stirring it over 
night. Cells were washed once in PBS and then and fixed with 10% formalin (Sigma) for 
30 minutes at RT. The working Oil-Red-O solution was prepared mixing 3 parts of the 
stock solution with 2 parts of ddH2O. Fixed cells were washed once to remove the formalin 
with water and then treated 5 minutes with 60% isopropanol; then they were treated for 5 
minutes with the working solution. After the treatment cells were washed with water to 
eliminate Oil-Red-O precipitates. For Osteocytes differentiation CFU-F forming MSCs 
were collected and re-plated at a density of 20.000 cells/well in a 12-wells plate. Once 
reached 40% confluence, cells were treated with StemXVivo Osteogenic/Adipogenic 
medium (R&D Systems, CCM007) together with osteogenic supplement (R&D Systems, 
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CCM009). Medium was changed every three days for 20 days. Mature osteoblasts were 
stained with Leukocyte Alkaline Phosphatase kit (Sigma Cat. 85L3R) according to the 
manufacturer procedures. For chondrocytes differentiation 150.000 MSCs were pelleted in 
StemXVivo Chondrogenic medium (R&D Systems, CCM005) with chondrogenic 
Supplement (R&D Systems, CCM006). Tubes were then incubated at 37° C and 5% CO2 
with loosen cap. Medium was changed every 3-4 days for 20 days. Micro-masses were then 
collected, embedded into paraffin, sectioned and stained with Toluidine Blue.  
Flow cytometry 
Cells were analyzed using LRSII (BD, Pharmingen) and sorted using FACS-ARIA II (BD, 
Pharmingen). The following antibodies were used: anti-CD45 FITC, anti-CD31 FITC, anti-
Ter119 FITC, anti-Sca1 Pacific Blue, anti-PDGFR PE (all purchased from Biolegend); 
Annexin-V PE (BD, pharmingen).  
Immunofluorescence 
Cells were fixed with 4% PFA for 10 minutes, washed with PBS and permeabilized with 
PBS, Triton-X100 0.2% for 10 minutes. Blocking before antibodies has been performed in 
PBS, Triton-X100 0.2% and 10% FBS for 30 minutes. Primary antibody p-histone H2AX 
(Cell Signaling) was incubated over night in blocking buffer, and an anti-Rabbit-488 was 
used as secondary antibody. 
Immunohistochemistry and human tumor samples 
A TMA (Tissue Microarray) of human fibrous tissue, fibromas, fibrosarcomas and 
Malignant fibrous histiocytomas was purchased from US Biomax, Inc. (SO2084). IHC was 
performed on 5-mm paraffin sections with the avidin-biotin-peroxidase method. The 
following primary antibody was used: LRF (Bethyl lab, cat # A300-549) 1:400 for human 
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staining. Antigen retrieval was performed using citrate buffer. Samples were evaluated 
assessing the overall positivity of the neoplastic tissue and comparing it with normal 
fibrous tissue. 
Luciferase assay 
One day before transfection, cells were plated into 24-well plate at a density of 70-80%. 
The cells were transfected with the plasmids DNA (pGl3-Luc-Dlk1 promoter and pcDNA3-
Lrf) and lipofectamine 2000 (Invitrogen) for 24 hours according to the manufacturer’s 
recommendation. 48 hours post-transfection, cells were lysed and analyzed for luciferase 
activity using the Dual-luciferase assay system (Promega). pRL-SV40-Renillar was used a 
control for transfection efficiency. 
EMSA 
Electrophoretic Mobility Shift Assay—For EMSA, 3T3L1 cells were resuspended in lysis 
buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.5% Nonidet P-40, 150 mM NaCl, 1 mM 
dithiothreitol, 10% glycerol, 0.5 mM phenylmethylsulfonyl fluoride, and protease 
inhibitors). After 20 min on ice, extracts were centrifuged at 16000 × g for 20 min at 4 °C 
to remove cell debris. Protein concentration in supernatants was determined using Bio-Rad 
protein assay. A 26-mer DNA oligonucleotide containing the Dlk1 promoter sequence with 
putative Lrf binding site (5′-GGCTCGTCGGAGGGCTTCGGCTTTTC-3′) was end-
labeled with 32P ((10 μM oligonucleotide, 1 μl kinase buffer 10 × (40 mM, Tris–HCl pH 
7.5, 10 mM MgCl2, 5 mM dithiothreitol), 2 μl ATP (ATP (ϒ-32P) (5,000 Ci mmol
−1
)) and 
0.5 μl of the kinase (10 units μl−1)) and annealed to the complementary strand. For binding 
reactions, 30 μg of whole cell extract were added to gel shift buffer (20 mm HEPES pH 8, 
25 mm KCl, 0.1 mm EDTA, 2 mm MgCl2, 0.5 mm dithiothreitol, 0.025% Nonidet P-40, 2 
mm spermidine, 10% glycerol, 0.1 mg/ml acetylated bovine serum albumin, 120 ng of 
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double-stranded poly(d[I-C])) containing the labeled oligonucleotide in a final volume of 
30 μl. Reactions were incubated for 30 min at room temperature, and electrophoresed on a 
non-denaturing 4% polyacrylamide gel before autoradiography. Supershift was obtained by 
adding 500ng of anti-LRF antibody (13E9) to the binding reaction.   
Chromatin immunoprecipitation 
Chromatin immunoprecipitation was performed as described (54) with the Magna ChIP G 
Chromatin Immunoprecipitation Kit (Millipore) using a hamster monoclonal antibody 
against Pokemon (LRF) (33).  Primer sequences used for PCR were as follows: 
Dlk1_4,5_Fwd: cccagggacaggcagtaaggtt, Dlk1_4,5_Rev: ccaaacgcacaccacgaagat. 3T3L1 
cells were crossed linked with formaldehyde for 5 minutes and terminated with 0.125M 
glycine. Cells were sonicated to generate chromatin with average size of 500bp. 
Monocloncal anti-LRF antibody were first incubated with a hamster bridging antibody 
(Jackson ImmunoResearch Laboratories), followed by addition of the 3T3L1 chromatin. 
Immunoprecipitated chromatin was assayed by quantitative PCR using the Dlk1-specific 
primers.  
Viral vectors 
Lentiviral vector expressing CRE, shCTR and shLRF, and retroviral vectors containing c-
myc, and K-Ras
G12V
 were obtained from Addgene. Viral vectors of control as well as 
containing shRNA against Lrf, Pml, Pten, Dlk1 and Sox9 were obtained from open 
biosystem. Vectors containing IDH2
R172K
 were cloned in our lab. All the viral particles 
were produced in transfecting 293T cells with packaging vectors of second generation. 
Anchorage-independent cell growth 
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Soft agar colony formation assay was carried out seeding 1 × 10
4
 MSCs in DMEM 
containing 0.4% low-melting agarose and 10% FCS. The cells were then plated in six wells 
plates previously coated with DMEM containing 1% of low-melting agarose and 10% FCS. 
The number of colonies was scored 3 weeks later, and quantification has been done using 
ImageJ. 
Focus formation assay 
MSCs were seeded at a concentration of 1x10
5 
cell per well in a 6-wells plate and cultured 
for 10 days in complete medium (DMEM + 10% FBS) at 37°C. Once the formed visible 
foci cells were fixed with 10% formalin for 30 minutes, and the stained with crystal violet.  
In vivo sarcomagenesis 
As previously described, 3D scaffolds made with reticulated polycarbonate polyurethane 
urea matrix (Synthecon) were used (24). Briefly, scaffolds (5mm x 2mm) were put into the 
wells of a 96-wells plated, and seeded with MSCs at a concentration of 1x10
5
 cells/scaffold. 
Wells were completely filled with 200μl of complete MesenCult medium, and left in 
culture (in regular oxygen concentration) for at least 6 hours. Scaffolds were washed with 
PBS in order to eliminate not attached cells, and implanted sub-cutaneoulsy into mice 
flanks. When recovered scaffolds/tumors were fixed in formalin and embedded into 
paraffin, sectioned and stained then with hematoxylin and eosin. Animal experiments were 
performed in accordance with the guidelines of the Beth Israel Deaconess Medical Center 
Institutional Animal Care and Use Committee. Pathological analysis of the tumors has been 
performed at Dana-Farber Rodent Histopathology Core. 
Western blot  
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For western blot, cell lysates were prepared with RIPA buffer. The following antibodies 
were used: hamster anti-Lrf clone 13E9, rabbit polyclonal anti-cPARP (Cell Signaling Cat. 
9532), mouse polyclonal anti--actin (Sigma-aldrich), and mouse monoclonal anti-HSP90 
(BD Biosciences).  
Senescence detection 
MSCs were cultured in hypoxia, before and for 4 days after the transduction. After the 
transduction cells were collected and seeded 10 x 10
5
 cells/well in a 12-well-plate. Cells 
were then treated with SA--galactosidase over night. Senescence was detected using 
senescence detection kit (Calbiochem) following the manufacturer protocol.    
Plasmids 
The entire Dlk1 mouse promoter sequence was obtained by PCR from a BAC clone. FW 
(5’ ccgagctcgggagtgccatttcatttaa 3’) and RV (5’ ccgctagcaaagccagcaggagcaagag 3’) primers 
were used. The fragment was cloned into pGL3-Luc enhancer (Promega) in SacI and NheI 
sites. All the mutants were obtained by using the Quickchange mutagenesis kit (Stratagene) 
and confirmed by sequencing. The mutated version of this plasmid was generated by 
utilizing the Dlk1 3′UTR as template and modifying the putative Lrf binding sites using the 
QuikChange II XL Site-Directed Mutagenesis Kit.  
The mutagenic primers used were:  
site Mutant 1AB forward 5’-ggaagggaaaatggagtctagagacggggagagactcacctcactagtctggg-3’ 
reverse 5’-ccttcccttttacctcagatctctgcccctctctgagtggagtgatcagaccc-3’;  
site Mutant 2 forward 5’-gggctcacctcactagtctagagttccttgtactctatgtgcccc-3’  
reverse 5’-cccgagtggagtgatcagatctcaaggaacatgagatacacgggg-3’;  
site Mutant 3 forward 5’-ggagcccttatctcaggaatctagccccaagatcctctc-3’  
reverse 5’-cctcgggaatagagtccttagatcggggttctaggagag-3’;  
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site Mutant 4 forward 5’-tgtgccgaaaggtgtgtttgggttagagattcgtggggcaagtgc-3’  
reverse 5’-acacggctttccacacaaacccaatctctaagcaccccgttcacg-3’;  
site Mutant 5 forward 5’-caatggcaaggctcgtcgaaagacctcggcttttcgtggtggt-3’  
reverse 5’-gttaccgttccgagcagctttctggagccgaaaagcaccacca-3’.  
RNA extraction and RT-PCR 
Cellular RNA was extracted using Quick-RNA MicroPrep (Zymo Research, R1050) and 
then retro-transcribed to cDNA using iScript cDNA Synthesis kit (Bio-Rad, 170-8890). All 
the analyzed mRNA was detected using TaqMan FAM-conjugated probes (Applied 
Biosystems). Each target was run in triplicate and expression level was normalized to 
mouse 2-microglobulin. Details are provided in Supplemental Experimental Procedures.  
Taq-Man RT-PCR probes 
All the probes were purchased from Applied Biosystems. 
2-microglobulin: Mm00437764_m1 
Sox9: Mm00448840_m1 
Mia:  Mm00444563_m1 
Col2: Mm01309565_m1 
Col9: Mm00483836_m1 
Col10: Mm00487041_m1 
c/ebp: Mm00786711_s1 
Runx2: Mm00501584_m1 
Fabp4: Mm00445878_m1 
PPAR: Mm01184322_m1 
ALP: Mm00475834_m1 
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Osteocalcin (OC): Mm00649782_gH 
Zbtb7a: Mm00657132_m1 and ZBTB7A: Hs00792219_m1 
Dlk1: Mm00494477_m1  
Hes1: Mm01342805_m1 
Hey1: Mm00468865_m1 
p21: Mm04205640_g1 
MIA: Hs00197954_m1  
H19: Hs00262142_g1  
LRF: Hs00252415_s1 
DLK1: Hs00171584_m1 
FABP4: Hs01086177_m1 
 
Statistic 
Data were analyzed using unpaired t-test (GraphPad Prism, GraphPad Software, Inc.). 
Values of P < 0.05 were considered statistically significant. *P < 0.05; **P < 0.01; ***P < 
0.001 (t-test). 
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FIGURE LEGENDS 
Figure 1. New genetic platform to study genes responsible for sarcomagenesis. (A) MSCs 
were isolated from the bone marrow of p53
KO
 mice as CD31
-
CD45
-
Ter119
-
Sca1
+
PDGFR+, and cultured at 1% of oxygen. After 7 days in culture cells formed visible 
CFU-F colonies. (B) Growth curve with wild type MSCs maintained in culture for less then 
10 passages or more than 30 passages before the day 0 of the proliferation assay. Results 
are shown as one representative experiment out of 2 independent biological replicates.  (C) 
Scaffolds seeded with wild type MSCs isolated from bone marrow and grown 7 days in 
hypoxic conditions. The chart on the left show the size of the collected scaffolds, while the 
pictures on the right are section of the scaffolds showing blood vessels, and not transformed 
mesenchymal cells. n=6 mice implanted with scaffolds. (D) Growth curve of wild type or 
p53
KO 
MSCs isolated from bone marrow and maintained for more than 30 passages in 
hypoxic conditions is shown on the left, while foci formation assay (lower panel) and 
growth in anchorage-independent manner (soft agar, upper panel) performed with p53
KO 
MSCs are shown on the right. Results are shown as one representative experiment out of 3 
independent biological replicates. (E) Schematic overview of the experimental design. The 
tumorigenic potential of MSCs cultured in hypoxic conditions was assessed seeding cells 
into scaffolds and implanting them subcutaneously into mice. Two serial implantations 
have been performed. (F) Representative pictures of scaffolds seeded with p53
KO 
MSCs, 
and implanted subcutaneously in mice are shown on the left, while H&E staining of 
scaffold sections are shown on the right. Charts below the pictures of the scaffolds 
represent the size of the scaffolds collected from mice (from 1
st
 recipient on the left, as well 
from the 2
nd
 recipient on the right), compared to the size of the scaffold before its 
implantation. The upper right picture shows the blood vessels recruited by cells within the 
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scaffold. The lower right pictures shows non-transformed mesenchymal cells seeded within 
the scaffold. (G) Focus formation assay with p53
KO
 MSCs cultured for one month or 4 
months at 20% of oxygen or 1% of oxygen. Quantification of transformed foci is shown on 
the left while representative pictures are shown on the right. Results are shown as one 
representative experiment out of 2 independent biological replicates. (H) Foci formation 
assay performed with p53
KO 
MSCs transduced in vitro with vectors expressing c-myc, K-
Ras
G12V
 and IDH2
R172K
, or silenced with shRNA for PML, PTEN and LRF The carts shown 
on the left represent the quantification of the observed foci of transformation. n=3 
independent biological experiments.  
 
Figure 2. Lrf loss in MSCs leads to formation of mesenchymal tumors. (A) Soft-agar assay 
for detecting anchorage independent cell growth of p53
KO
Zbtb7a
F/F
-CTR and
 
p53
KO
Zbtb7a
F/F
-CRE MSCs. Representative pictures of the colonies are shown on the left, 
while the quantification on the right is shown as average of 3 biological independent 
replicates ± SEM. (B) Schematic overview of the experimental design is shown on the left, 
while the percentage of mice with a tumor bigger that 0.5 cm
3 
is shown on the right. 
p53
KO
Zbtb7a
F/F
-CTR cells were not transformed, and only scaffolds within mesenchymal 
cells were recovered after transplantation. (n=2 CTR, n=2 CRE). (C) Detection of 
transformation status of p53
KO
Zbtb7a
F/F
-CTR or
 
p53
KO
Zbtb7a
F/F
-CRE cells. Pictures of the 
foci are shown on the left, while the quantification of the transformed foci is shown on the 
right. The quantification on the right is shown as pooled from 3 independent experiments, 
mean ± SEM. (D) Tumors generated by p53
KO
Zbtb7a
F/F
-CTR or
 
p53
KO
Zbtb7a
F/F
-CRE cells 
transplanted within scaffolds into second recipient mice. Representative pictures of mice 
are shown on the left, while the percentage of mice with a tumor bigger that 0.5 cm
3 
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(scaffold size used as control) is shown on the right. (n=4 CTR, n=7 CRE) (E) Sizes of 
tumors generated by p53
KO
Zbtb7a
F/F
-CTR or
 
p53
KO
Zbtb7a
F/F
-CRE cells transplanted within 
scaffolds into second recipient mice. Pictures of the collected tumors are shown on the left, 
while the relative size of tumors is shown on the right (scaffold size used as control). (F-G) 
Tumors generated by
 
p53
KO
Zbtb7a
F/F
-CRE cells compared p53
KO
Zbtb7a
F/F
-CTR cells 
collected from 1
st
 recipients, seeded into scaffolds and the transplanted into 2
nd
 recipients. 
H&E staining showing the morphology of collected tumors or mesenchymal cells on top of 
the scaffold. p53
KO
Zbtb7a
F/F
-CTR cells were not able to generate tumors in vivo and only 
scaffolds within mesenchymal cells were recovered after transplantation, while 
p53
KO
Zbtb7a
F/F
-CRE cells originated undifferentiated sarcomas. (* indicates the scaffold. 
Scale bars: 20 μm). (H) LRF expression in human undifferentiated sarcomas. (M.F.H. 
malignant fibrous hystocytoma; F. fibrosarcomas; N.F.T. normal fibrous tissue; scale bars 
30μm). 
 
Figure 3. Lrf is a key factor for MSCs commitment and differentiation. (A) MSCs 
differentiation into mature adipocytes. Adipocytic colonies stained with Oil-Red-O are 
shown on the left, while the relative quantification of adipocytic colonies (positive for Oil-
Red-O) among the total number of colonies (CFU-F) is shown on the right. The 
quantification on the right is shown as average of 5 independent experiments ± SEM. (B) 
Lrf, Pparγ and Fabp4 relative mRNA expression in CTR-cells and CRE-cells during 
adipogenesis. Results are shown as one representative experiments out of 2 independent 
biological replicates. (C) MSCs differentiation toward mature osteoblasts. Representative 
pictures of Alp
+
 cells are shown one the left while the relative number of Alp
+
 cells is 
shown on the right. The quantification on the right is the average of 3 independent 
 35 
experiments ± SEM. (D) Lrf, Alp and Oc relative mRNA expression in CTR-cells and 
CRE-cells during osteogenesis. Results are shown as one representative experiments out of 
2 independent biological replicates. (E) MSCs differentiation toward chondrocytes. 
Representative images of chondrocytes originated from CTR-cells and CRE-cells stained 
with Toluidine blue are shown on the left (n=2 independent biological replicates). Relative 
mRNA expression levels of Lrf, Col2, ColIX and ColX are shown on the right. Results are 
shown as average of 2 independent biological replicates ± SEM. (F) Morphology of human 
MSCs transduced with shCTR or shLRF and cultured at 1% of oxygen. (G) Human MSCs 
transduced with shCTR or shLRF and induced to adipogenesis, at day 7 of the 
differentiation process. Magnification shows in detail fully differentiated adipocytes. (H) 
Human MSCs differentiation into adipocytes, at day 15 of the differentiation process. 
Adipocytes stained with Oil-Red-O are shown in the top panel, while the relative mRNA 
expression of FABP4 is shown in the chart. 
 
Figure 4. Lrf regulates the differentiation process of MSCs through the repression of Dlk1. 
(A) Relative mRNA expression levels of Lrf, Mia and Col2a2 in CTR-cells and CRE-cells. 
Results are shown as one representative experiments out of 2 independent biological 
replicates. (B) Relative mRNA expression levels of LRF, H19 and MIA in human MSCs 
transduced with shCTR or shLRF. (C) Adipogenesis potential of CTR-shSCR-cells, CRE-
shSCR-cells and CRE-shSox9-cells. Adipocytic colonies stained with Oil-Red-O (upper 
panels) or crystal violet (lower panels) are shown on the left, while the relative 
quantification of adipocytic colonies is shown on the right. The quantification on the right 
is presented as average of 3 independent experiments ± SEM. (D) Osteogenesis potential of 
CTR-shSCR-cells, CRE-shSCR-cells and CRE-shSox9-cells. Representative pictures of 
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Alp staining are shown on the left, while the relative numbers of Alp
+ 
cells are shown on 
the right. The quantification on the right is presented as average of 3 independent 
experiments ± SEM.  (E) Lrf and Dlk1 relative mRNA expression in CTR-cells and CRE-
cells. Results are shown as average of 5 biological independent replicates ± SEM. (F) 
Relative mRNA expression levels of LRF and DLK1 in human MSCs transduced with 
shCTR or shLRF. (G) Luciferase assay for detecting the activity of Lrf on Dlk1 promoter. 
Results are shown as average of 3 biological independent replicates ± SEM. (H) EMSA 
assay showing a shift in presence of a specific probe representative for binding site #4 and a 
super-shift in presence of anti-Lrf antibody. (I) Chromatin immunoprecipitation of Lrf and 
Dlk1 promoter region. Results are shown as average of 3 biological independent replicates 
± SEM. (J) Adipogenesis potential of CTR-shSCR-cells, CRE-shSCR-cells and CRE-
shDlk1-cells. Adipocytic colonies stained with Oil-Red-O (upper panels) or crystal violet 
(lower panels) are shown on the left while the relative quantification of adipocytic colonies 
is shown on the right. The quantification on the right is presented as average of 3 biological 
independent replicates ± SEM. (K) Relative mRNA expression levels of Pparγ and Fabp4 
in adipocytes derived from CTR-shSCR-cells, CRE-shSCR-cells and CRE-shDlk1-cells. 
Results are shown as average of 3 biological independent replicates ± SEM. (L) 
Osteogenesis potential of CTR-shSCR-cells, CRE-shSCR-cells and CRE-shDlk1-cells. 
Representative pictures of Alp staining are shown on the left, while the relative numbers of 
Alp
+ 
cells is shown on the right. The quantification on the right is presented as average of 3 
biological independent replicates ± SEM. (M) Alp and Oc relative mRNA expression in 
osteoblasts derived from CTR-shSCR-cells, CRE-shSCR-cells and CRE-shDlk1-cells. 
Results are shown as average of 3 biological independent replicates ± SEM. 
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Figure 5. Lrf plays a role as oncosuppressor gene in mesenchymal tumor through Dlk1 and 
Sox9. (A) Schematic overview of the experimental design is depicted on the left, while the 
growth curve of p53
KO
Zbtb7a
F/F
-CTR-shSCR,
 
p53
KO
Zbtb7a
F/F
-CRE-shSCR,
 
p53
KO
Zbtb7a
F/F
-CRE-shDlk1 and p53
KO
Zbtb7a
F/F
-CRE-shSox9 cells is shown on the right. 
Data show one representative experiment out of 3 independent biological replicates. (B) 
Detection of transformation status of p53
KO
Zbtb7a
F/F
-CTR-shSCR,
 
p53
KO
Zbtb7a
F/F
-CRE-
shSCR,
 
p53
KO
Zbtb7a
F/F
-CRE-shDlk1 and p53
KO
Zbtb7a
F/F
-CRE-shSox9 cells. Pictures of the 
transformed foci are shown on the left, while their quantification on the right is presented as 
average of 3 biological independent replicates ± SEM. (C) Experimental design for in vivo 
sarcomagenesis is shown in the left panel, while the percentage of mice with tumor is 
shown on the right. (D) Representative pictures of tumors generated by p53
KO
Zbtb7a
F/F
-
CTR-shSCR,
 
p53
KO
Zbtb7a
F/F
-CRE-shSCR,
 
p53
KO
Zbtb7a
F/F
-CRE-shDlk1 and 
p53
KO
Zbtb7a
F/F
-CRE-shSox9 cells implanted within scaffolds into recipient mice (n=4 
CTR-shSCR, n=4 CRE-shSCR, n=5 CRE-shDlk1, n=5 CRE-shSox9) are shown on the left 
while the relative size of tumors is shown on the right (scaffold size used as control). (E) 
Representative H&E staining showing the morphology of collected tumors or mesenchymal 
cells on top of the scaffold. p53
KO
Zbtb7a
F/F
-CTR cells were not able to generate tumors in 
vivo and only scaffolds within mesenchymal cells were recovered after transplantation, 
while p53
KO
Zbtb7a
F/F
-CRE cells, p53
KO
Zbtb7a
F/F
-CRE-shDlk1 and p53
KO
Zbtb7a
F/F
-CRE-
shSox9 cells originated undifferentiated sarcomas. (* indicates the scaffold. Scale bars: 20 
μm). (F) Schematic overview of the genetic platform for discovering new oncopathways 
involved within the sarcomagenesis process, and new targeted-therapies (G) Schematic 
overview of Lrf involvement as tumor suppressor gene in undifferentiated sarcomas. 
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Lrf/Dlk1 and Lrf/Sox9 pathways are examples of results obtained with the application of 
the genetic platform. 
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